North China Pharmaceutical: 7 products newly included in the National Medical Insurance Catalog

North China Pharmaceutical announced that the company and its subsidiaries have a total of 240 products included in the 2026 edition of the National Medical Insurance Catalog, of which 113 are Class A and 127 are Class B, with no products removed this time. Seven products were newly included, including the Class 1 innovative drug omutivimab injection, tacrolimus capsules, cefprozil tablets, letermovir injection, roxadustat capsules, edoxaban tosylate tablets, and nadroparin calcium injection. The total sales revenue of the above newly included products in 2025 was 170 million yuan, and the total sales revenue in the first three quarters of 2026 was 121 million yuan. This inclusion will have a positive impact on product market expansion, and is not expected to have a material impact on operating performance in the short term.